Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 67 clinical trials
None
Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

infusion of CD19 and BCMA CAR-T cells can clear the B cells and plasma cells, can help increase platelet levels and reduce bleeding in patients with platelet transfusion refractoriness. To see if

  • 0 views
  • 06 Nov, 2021
  • 1 location
None
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

This Phase I/II study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible

cyclophosphamide
measurable disease
plasmacytoma
fludarabine
platelet count
  • 47 views
  • 19 Feb, 2021
  • 7 locations
None
A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Specificity CD38 and BCMA CAR-T cells can recognize and kill the malignant cells through recognition of CD38 or BCMA. This is a phase 1/2 study designed to determine the safety of dual specificity CD38 and

refractory multiple myeloma
bcma
  • 4 views
  • 22 Jan, 2021
  • 1 location
None
Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma

In patients with multiple myeloma with recurrent or refractory BCMA, CAR-T cell infusion was performed after screening, blood collection and pretreatment. Starting dose for 5 x 10^5 / kg, 1 x 10

calcium
neutrophil count
fludarabine
platelet count
lenalidomide
  • 9 views
  • 25 Jan, 2021
  • 1 location
None
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

The purpose of this study is to evaluate the safety and efficacy of BiRd regimen combined with BCMA CAR T cell therapy in newly diagnosed multiple myeloma patients

lenalidomide
dexamethasone
bcma
ejection fraction
  • 0 views
  • 02 Nov, 2021
  • 1 location
None
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

lupus
  • 0 views
  • 10 Sep, 2021
  • 1 location
None
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

sjogren's syndrome
  • 0 views
  • 28 Oct, 2021
  • 1 location
None
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

nephritis
  • 0 views
  • 30 Oct, 2021
  • 1 location
None
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

A phase 1b, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.

measurable disease
daratumumab
immunomodulatory imide drug
proteasome inhibitor
refractory multiple myeloma
  • 55 views
  • 07 Mar, 2021
  • 8 locations
None
Descartes-11 in Multiple Myeloma

This Phase I/2 study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible

cyclophosphamide
measurable disease
fludarabine
chemotherapy regimen
bcma
  • 30 views
  • 17 Feb, 2021
  • 4 locations